The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds
February 8th 2022Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Read More
Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars
January 26th 2022Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.
Read More
Patents Filed a Decade Post Originator Approval Account for Most Biosimilar Patent Lawsuits
January 21st 2022Researchers have found that most US patent infringement cases against biosimilar manufacturers cover patents filed over a decade after the originator product's FDA approval, leading to limits on competition among biologic drugs.
Read More
Ophthalmology Biobetters and Biosimilars May Be Just Around the Corner
January 12th 2022More biobetter drugs may be on the horizon, with an opportunity to snatch market share from reference products, and several biosimilars are under development for ophthalmic conditions, authors of a review concluded.
Read More
Projected US Savings From Biosimilars, 2021-2025
Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Read More
Findings Are Reported From De-escalation Therapy in Early Breast Cancer
December 15th 2021Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.
Read More
Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer
December 7th 2021Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.
Read More
AMCP Nexus Survey: Two-Thirds of Payers Use Biosimilars to Manage Oncology Drug Costs
November 23rd 2021As the cost of oncology drugs increases, there has been a growing pressure to manage oncology drug spend, which some payers have done by establishing preferred therapies, including biosimilars.
Read More
FDA Deputy Director Discusses Initiatives to Advance Biosimilar Use
November 9th 2021An overview of activities at the FDA to promote the use of biosimilars was presented by Jacqueline Corrigan-Curay, JD, MD, principal deputy center director for the Center for Drug Evaluation and Research (CDER) at the FDA.
Read More
Dr Cate Lockhart Discusses Deciding Between Trastuzumab Biosimilars
October 28th 2021There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.
Watch
Adalimumab Biosimilar Shows Equivalent Efficacy, Safety to Reference Humira for Psoriasis
October 20th 2021Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis.
Read More